Receptor Tyrosine Kinases in Osteosarcoma: Not Just the Usual Suspects

摘要: Despite aggressive surgical and chemotherapy protocols, survival rates for osteosarcoma patients have not improved over the last 30 years. Therefore, novel therapeutic agents are needed. Receptor tyrosine kinases emerged as targets development of new cancer therapies since their activation leads to enhanced proliferation, survival, metastasis. In fact, aberrant expression RTKs been associated with progression many cancers. Studies from our lab using phosphoproteomic screening identified that activated thus may contribute signaling within metastatic human cells. Functional genomic siRNA was performed distinguish which in vitro phenotypes potential (motility, invasion, colony formation, cell growth). The resulting RTK hits were then validated independent validation experiments. From these results, we four (Axl, EphB2, FGFR2, Ret) previously studied provide therapeutics.